ESR1 and breast carcinoma: The use of tamoxifen to prevent and treat ER+ breast cancer is due to its antagonistic effect in breast tissue (Dutertre and Smith, 2000; O’Regan and Jordan, 2002; Cuzick et al., 2013) and due to its effectiveness has been dubbed the gold standard of hormone therapy.